Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0027960 (
mole
)
21,279
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Transcriptional silencing of
tissue factor pathway inhibitor 2
(
TFPI2
) occurs in several human tumors including melanoma. We investigated methylated
TFPI2
as a biomarker of metastatic melanoma using qRT-PCR to assess
TFPI2
expression and pyrosequencing to analyze CpG island methylation in malignant melanoma cell lines, in benign nevi, in 112 primary and metastatic melanomas, and in serum from 6 healthy individuals and 35 patients: 20 patients with primary and 15 patients with metastatic melanoma. The
TFPI2
CpG island is unmethylated in
nevi
but methylation is associated with metastatic melanoma. Circulating methylated
TFPI2
DNA is undetectable in sera from healthy individuals and detectable in sera from patients with primary and metastatic melanomas, but the presence of methylated
TFPI2
DNA in serum is strongly associated with metastatic disease (P<0.01). Detection of
TFPI2
-methylated DNA in the serum of patients with resected melanoma is a sensitive and specific biomarker of metastatic melanoma. Confirmation of our results in independent patient cohorts would encourage prospective evaluation as a biomarker of disease state.
...
PMID:Methylated tissue factor pathway inhibitor 2 (TFPI2) DNA in serum is a biomarker of metastatic melanoma. 2430 58